Higher rates of osteoporosis were reported in those taking aromatase inhibitors compared with those taking tamoxifen, whereas endometrial abnormalities, including uterine polyps and endometrial cancers, were more frequent in those receiving tamoxifen (appendix pp 19–20). The gene discussed is CYP19A1; the disease is uterine polyp.